Terminated PHASE2 INTERVENTIONAL 1-arm NCT01485536

A Study of the HSP90 Inhibitor AUY922

A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma

Sponsor: M.D. Anderson Cancer Center

Conditions Lymphoma

Interventions AUY922

Updated 7 times since 2017 Last updated: Nov 28, 2016 Started: Aug 31, 2012 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study halted early due to limited response.

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

Other Lymphoma trials with similar outcome

Browse all Lymphoma trials

Listed as NCT01485536, this PHASE2 trial focuses on Lymphoma and remains terminated or withdrawn. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Novartis

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States